Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Labor/HHS

This article was originally published in The Tan Sheet

Executive Summary

Office of Dietary Supplements urged to "continue and expand" research initiative on ephedra safety and efficacy under Senate appropriations bill passed Oct. 11. ODS, NCCAM have commissioned an AHRQ study on ephedra, which could be released as early as August 2002 (1"The Tan Sheet" Aug. 13, p. 10). Appropriations bill also urges ODS to "allocate sufficient funds to expand the number of botanical research centers," with hypericum, echinacea suggested subjects of study. Bill would allocate NCCAM $110 mil. for FY 2002 (2"The Tan Sheet" Oct. 15, In Brief)
Advertisement

Related Content

ODS Methods, Reference Materials Program To Be Directed By AHPA’s Betz
ODS Methods, Reference Materials Program To Be Directed By AHPA’s Betz
Labor/HHS appropriations
AHRQ Ephedra Evidence Report Targeted For August 2002 Release
AHRQ Ephedra Evidence Report Targeted For August 2002 Release

Topics

Advertisement
UsernamePublicRestriction

Register

PS093175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel